Table 2.
Primary outcome of hip cartilage metabolism assessed by dGEMRIC (ms): Change from Baseline (B) to 12 month (12 M) assessments (N = 53)
| Outcome | Arthroscopy (N = 27) | PHT (N = 26) | Arthroscopy - PHT | |||||
|---|---|---|---|---|---|---|---|---|
| n | Mean (SD or 95% CI) | n | Mean (SD or 95% CI) | Unadjusted difference | P-valuea | Adjusted difference (95% CI) | P-valueb | |
| dGEMRIC Combined (primary outcome) | ||||||||
| Baseline | 26 | 679.6 (118.6) | 24 | 667.0 (127.4) | ||||
| 12 month | 21 | 677.0 (122.8) | 23 | 722.8 (145.7) | ||||
| Change: 12 M-B | 20 | −14.8 (−73.8–44.2) | 21 | 48.4 (−16.6–113.5) | −63.2 | 0.142 | −59.1 (− 137.9–19.6) | 0.137 |
| dGEMRIC Acetabular ROI | ||||||||
| Baseline | 26 | 661.2 (121.1) | 24 | 637.2 (145.3) | ||||
| 12 month | 21 | 618.5 (130.5) | 23 | 651.8 (145.0) | ||||
| Change: 12 M-B | 20 | −63.0 (−120.2 - -5.9) | 21 | 7.1 (−55.5–69.7) | −70.1 | 0.093 | −58.9 (− 134.8–17.1) | 0.125 |
| dGEMRIC Femoral ROI | ||||||||
| Baseline | 26 | 698.9 (137.0) | 24 | 698.4 (125.4) | ||||
| 12 month | 21 | 735.8 (135.6) | 23 | 789.8 (170.8) | ||||
| Change: 12 M-B | 20 | 34.1 (−37.6–105.7) | 21 | 84.2 (8.9–159.5) | −50.1 | 0.321 | −55.4 (− 149.5–38.6) | 0.240 |
| dGEMRIC Z-score | ||||||||
| Baseline | 26 | −0.49 (0.70) | 24 | −0.45 (0.67) | ||||
| 12 month | 21 | − 0.50 (0.51) | 23 | −0.69 (0.54) | ||||
| Change: 12 M-B | 20 | 0.16 (−0.21–0.53) | 21 | −0.20 (− 0.63–0.23) | 0.36 | 0.199 | 0.24 (−0.11–0.58) | 0.169 |
aPaired t-test
bBased on regression model including adjustment for baseline